As mentioned, our previous findings demonstrate BP1 expression in 100% of estrogen-receptor-alpha-negative breast cancers studied, compared with 73% of estrogen-receptor-alpha-positive tumors [11]. This evidence concerns the gene DLX4 and breast cancer.